

Application No.: 10/018,386  
Filing Date: May 17, 2002

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Attorney Docket No. MSB-7268 PCT-US)

RECEIVED  
CENTRAL FAX CENTER

AUG 26 2004

In re the Application of:

FRIEDRICH ET AL.

Application No.: 10/018,386

Filing Date: May 17, 2002

For: METHODS FOR MODULATING  
ANGIOGENESIS BY USING THE  
ANTI-ANGIOGENIC ANGIOTENSIN-7  
AND POLYNUCLEOTIDES ENCODING  
THEREFOR

Examiner: NICKOL, GARY B.

Art Unit: 1642

Confirmation No.: 7895

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


**RESPONSE TO RESTRICTION REQUIREMENT MAILED JULY 29, 2004**

Sir:

In Response to the Office Action (a Restriction Requirement mailed July 29, 2003), Applicants elect to prosecute the claims of Group 1, without traverse. The claims of Group 1 are Claims 1-6, 8-21, and 23-33 drawn to the special technical feature of methods of inhibiting angiogenesis and endothelial tube formation comprising administering an isolated Ang-7 polypeptide.

If, in the opinion of the examiner, a telephone conference would expedite the prosecution of this application, the examiner is invited to call the undersigned attorney.

Respectfully submitted,

  
John W. Mahoney  
Patent Counsel  
Bayer Pharmaceuticals Corporation  
Reg. No. 44,892  
Phone Number (510) 705-7725

Aug. 25, 2004

Dated: August 25, 2004

Customer Number 27169